CRISPR-Cas9 Technology for the Creation of Biological Avatars Capable of Modeling and Treating Pathologies: From Discovery to the Latest Improvements

Overview

Journal Cells

Publisher MDPI

Specialties Biochemistry
Biophysics
Cell Biology
Molecular Biology

Date 2022 Nov 26

PMID 36429042

Authors

Ali Nasrallah

Eric Sulpice

Farah Kobaisi

Xavier Gidrol

Walid Rachidi

Affiliations

Soon will be listed here.

Abstract

This is a spectacular moment for genetics to evolve in genome editing, which encompasses the precise alteration of the cellular DNA sequences within various species. One of the most fascinating genome-editing technologies currently available is Clustered Regularly Interspaced Palindromic Repeats (CRISPR) and its associated protein 9 (CRISPR-Cas9), which have integrated deeply into the research field within a short period due to its effectiveness. It became a standard tool utilized in a broad spectrum of biological and therapeutic applications. Furthermore, reliable disease models are required to improve the quality of healthcare. CRISPR-Cas9 has the potential to diversify our knowledge in genetics by generating cellular models, which can mimic various human diseases to better understand the disease consequences and develop new treatments. Precision in genome editing offered by CRISPR-Cas9 is now paving the way for gene therapy to expand in clinical trials to treat several genetic diseases in a wide range of species. This review article will discuss genome-editing tools: CRISPR-Cas9, Zinc Finger Nucleases (ZFNs), and Transcription Activator-Like Effector Nucleases (TALENs). It will also encompass the importance of CRISPR-Cas9 technology in generating cellular disease models for novel therapeutics, its applications in gene therapy, and challenges with novel strategies to enhance its specificity.

Citing Articles

CRISPR-Cas9 in Cardiovascular Medicine: Unlocking New Potential for Treatment.

Bonowicz K, Jerka D, Piekarska K, Olagbaju J, Stapleton L, Shobowale M Cells. 2025; 14(2).

PMID: 39851560 PMC: 11763404. DOI: 10.3390/cells14020131.

Generation and characterization of CRISPR-Cas9-mediated XPC gene knockout in human skin cells.

Nasrallah A, Rezvani H, Kobaisi F, Hammoud A, Rambert J, Smits J Sci Rep. 2024; 14(1):30879.

PMID: 39730601 PMC: 11681161. DOI: 10.1038/s41598-024-81675-6.

References

Wilson R, Gilbert L . The Promise and Challenge of In Vivo Delivery for Genome Therapeutics. ACS Chem Biol. 2017; 13(2):376-382. PMC: 5906052. DOI: 10.1021/acschembio.7b00680. View

Sanchez-Rivera F, Papagiannakopoulos T, Romero R, Tammela T, Bauer M, Bhutkar A . Rapid modelling of cooperating genetic events in cancer through somatic genome editing. Nature. 2014; 516(7531):428-31. PMC: 4292871. DOI: 10.1038/nature13906. View

Kowalczykowski S . An Overview of the Molecular Mechanisms of Recombinational DNA Repair. Cold Spring Harb Perspect Biol. 2015; 7(11). PMC: 4632670. DOI: 10.1101/cshperspect.a016410. View

KEELER C . THE GEOTROPIC REACTION OF RODLESS MICE IN LIGHT AND IN DARKNESS. J Gen Physiol. 2009; 11(4):361-8. PMC: 2140980. DOI: 10.1085/jgp.11.4.361. View

Ding Q, Strong A, Patel K, Ng S, Gosis B, Regan S . Permanent alteration of PCSK9 with in vivo CRISPR-Cas9 genome editing. Circ Res. 2014; 115(5):488-92. PMC: 4134749. DOI: 10.1161/CIRCRESAHA.115.304351. View

Paquet D, Kwart D, Chen A, Sproul A, Jacob S, Teo S . Efficient introduction of specific homozygous and heterozygous mutations using CRISPR/Cas9. Nature. 2016; 533(7601):125-9. DOI: 10.1038/nature17664. View

Pattanayak V, Lin S, Guilinger J, Ma E, Doudna J, Liu D . High-throughput profiling of off-target DNA cleavage reveals RNA-programmed Cas9 nuclease specificity. Nat Biotechnol. 2013; 31(9):839-43. PMC: 3782611. DOI: 10.1038/nbt.2673. View

Zhong H, Chen Y, Li Y, Chen R, Mardon G . CRISPR-engineered mosaicism rapidly reveals that loss of Kcnj13 function in mice mimics human disease phenotypes. Sci Rep. 2015; 5:8366. PMC: 4322368. DOI: 10.1038/srep08366. View

Mashimo T, Takizawa A, Voigt B, Yoshimi K, Hiai H, Kuramoto T . Generation of knockout rats with X-linked severe combined immunodeficiency (X-SCID) using zinc-finger nucleases. PLoS One. 2010; 5(1):e8870. PMC: 2810328. DOI: 10.1371/journal.pone.0008870. View

10.

Urnov F, Miller J, Lee Y, Beausejour C, Rock J, Augustus S . Highly efficient endogenous human gene correction using designed zinc-finger nucleases. Nature. 2005; 435(7042):646-51. DOI: 10.1038/nature03556. View

11.

Boch J, Scholze H, Schornack S, Landgraf A, Hahn S, Kay S . Breaking the code of DNA binding specificity of TAL-type III effectors. Science. 2009; 326(5959):1509-12. DOI: 10.1126/science.1178811. View

12.

Luo Y, Liu C, Cerbini T, San H, Lin Y, Chen G . Stable enhanced green fluorescent protein expression after differentiation and transplantation of reporter human induced pluripotent stem cells generated by AAVS1 transcription activator-like effector nucleases. Stem Cells Transl Med. 2014; 3(7):821-35. PMC: 4073825. DOI: 10.5966/sctm.2013-0212. View

13.

Karvelis T, Gasiunas G, Miksys A, Barrangou R, Horvath P, Siksnys V . crRNA and tracrRNA guide Cas9-mediated DNA interference in Streptococcus thermophilus. RNA Biol. 2013; 10(5):841-51. PMC: 3737341. DOI: 10.4161/rna.24203. View

14.

Vanamee E, Santagata S, Aggarwal A . FokI requires two specific DNA sites for cleavage. J Mol Biol. 2001; 309(1):69-78. DOI: 10.1006/jmbi.2001.4635. View

15.

Noh K, Park J, Kang M . Targeted disruption of EBNA1 in EBV-infected cells attenuated cell growth. BMB Rep. 2016; 49(4):226-31. PMC: 4915242. DOI: 10.5483/bmbrep.2016.49.4.260. View

16.

Huang P, Xiao A, Zhou M, Zhu Z, Lin S, Zhang B . Heritable gene targeting in zebrafish using customized TALENs. Nat Biotechnol. 2011; 29(8):699-700. DOI: 10.1038/nbt.1939. View

17.

Wu Y, Zhou H, Fan X, Zhang Y, Zhang M, Wang Y . Correction of a genetic disease by CRISPR-Cas9-mediated gene editing in mouse spermatogonial stem cells. Cell Res. 2014; 25(1):67-79. PMC: 4650588. DOI: 10.1038/cr.2014.160. View

18.

Jansen R, van Embden J, Gaastra W, Schouls L . Identification of genes that are associated with DNA repeats in prokaryotes. Mol Microbiol. 2002; 43(6):1565-75. DOI: 10.1046/j.1365-2958.2002.02839.x. View

19.

Wu W, Tsai Y, Justus S, Lee T, Zhang L, Lin C . CRISPR Repair Reveals Causative Mutation in a Preclinical Model of Retinitis Pigmentosa. Mol Ther. 2016; 24(8):1388-94. PMC: 5023380. DOI: 10.1038/mt.2016.107. View

20.

Meisel R . CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia. N Engl J Med. 2021; 384(23):e91. DOI: 10.1056/NEJMc2103481. View